A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease [Estudio fase III, multicentrico, aleatorizado, doble ciego controlado con farmaco activo, de 18 meses de duracion para comparar rosiglltazona frente a gllpizida en la progresion de la aterosclerosis en sujetos con diabetes mellltus tipo 2 y enfermedad cardiovascular]
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Rosiglitazone (Primary) ; Glipizide
- Indications Atherosclerosis; Coronary artery disease; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms APPROACH; IVUS
- Sponsors GlaxoSmithKline; GSK
- 12 Oct 2012 Planned number of patients changed from 600 to 634 as reported by European Clinical Trials Database record.
- 01 Mar 2010 Results were published online before print in Circulation.
- 01 Dec 2008 Study design and baseline characteristics were published in the American Heart Journal.